LONDON, June 5, 2017 /PRNewswire/ --
Biosimilar Versions of Infliximab, Rituximab, Trastuzumab,Adalimumab, Bevacizumab and Abciximab
The global biosimilar monoclonal antibodies market is expected to grow at a CAGR of 9.6% in the second half of the forecast period. The market is expected to grow at a CAGR of 23.8% from 2015-2027. The
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 204-page report you will receive 72 tables and 72 figures - all unavailable elsewhere.
The 204-page report provides clear detailed insight into the global biosimilar monoclonal antibodies market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand new report today you stay better informed and ready to act.
• Global Biosimilar Monoclonal Antibodies Market forecasts from 2017-2027
• Along with revenue prediction for the overall world market for biosimilar monoclonal antibodies, our investigation shows forecasts to 2027 for the market segmented by compound: - Infliximab - Rituximab - Abciximab - Trastuzumab - Adalimumab - Bevacizumab
• This report also shows revenue to 2027 for individual biosimilar mAb products in the market: - Remsima/Inflectra - Infimab - Reditux - BI695500 - CT-P10 - BI695501 - FKB327 - FKB238 - Mabtas - AcellBia - Maball - Clotinab - Abcixirel - BCD-022 - BCD-021 - Herzuma - CANMAB/Hertraz
• Our analyses show individual revenue forecasts to 2027 for these regional and national markets: - The US Biosimilar mAb Market - Japanese Biosimilar mAb Market - EU5 Biosimilar mAb Markets - BRIC and South Korea Biosimilar mAb Markets - Rest of the World Biosimilar mAb Market
• This report profiles 10 leading companies either with biosimilar mAbs already on the market or in the pipeline.
• Our study discusses strengths, weaknesses, opportunities and threats affecting the biosimilar monoclonal antibodies market.
Visiongain's study is intended for anyone requiring commercial analyses for the biosimilars monoclonal antibodies market. You find data, trends and predictions.
Buy our report today Global Biosimilar Monoclonal Antibodies Forecast 2017-2027: Biosimilar Versions of Infliximab, Rituximab, Trastuzumab, Adalimumab, Bevacizumab and Abciximab.
To request a report overviews of this report please email Sara Peerun at email@example.com or call Tel: +44-(0)-20-7336-6100. Or click on https://www.visiongain.com/Report/1875/Global-Biosimilar-Monoclonal-Antibodies-Forecast-2017-2027
Companies Mentioned in the Report
Celon Pharma ?omianki
Dr. Reddy's Laboratories
Fujifilm Kyowa Kirin Biologics
Gene Techno Science
Instituto Vital Brazil
Johnson & Johnson
Kyowa Hakko Kirin
LG Life Sciences
Merck & Co.
Mustafa Nevzat Pharmaceuticals
Nichi-Iko Pharmaceutical Co.
Reliance Life Sciences
Shanghai CP Guojian
Teva Pharmaceutical Industries
Zhejiang Huahai Pharmaceutical
To see a report overview please email Sara Peerun on firstname.lastname@example.org
SOURCE Visiongain Ltd
Subscribe to our Free Newsletters!
Sea food allergy is the adverse response of the body''s immune system to the proteins present in ...
Yellow fever is a hemorrhagic fever that is transmitted by infected mosquitoes and it can lead to ...
Routes of drug administration play a major role in a medical treatment. Selecting a right route of ...View All